Generic Name: Retevmo (selpercatinib)
Retevmo Reviews
For Non Small Cell Lung Cancer "I believe Retevmo to be a major part of why I am still alive today. Not expected to live to the end of 2020, I was given Retevmo by my cancer doctors in August of that year. Here I am now, a much more functioning person, in the workforce, and enjoying every day as I can! I take Retevmo 160mg twice daily, twelve hours apart (breakfast and dinner). Thank you, Eli Lilly, for sharing this drug with those who are fortunate enough to be able to take it."
For Non Small Cell Lung Cancer "Was diagnosed in Jan 2020 at 45 years old with stage 3b NSCLC. A year ago, it advanced to stage 4 when it spread to my bones (shoulder, spine, and pelvis). This is when I started taking Retevmo. I take 160 mg twice daily, and as of now, my cancer is stable. The main thing is, I had a lot of stomach discomfort and I developed enteritis a couple of months after I started taking it. Three months ago, I changed my diet and how I eat, and since then, no more stomach burning. Overall, it has been a positive experience. I feel great and live a very active life. I hope it continues to work."
For Non Small Cell Lung Cancer "Diagnosed NSCLC stage 4B March 2023. Began full dosage of Retevmo May 2023. First PET scan in August showed NED. Truly amazing! Now on 40 mg twice a day."
For Non Small Cell Lung Cancer "Retevmo Just makes me feel tired."
More about Retevmo (selpercatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
- Retevmo drug information
Professional resources
- Retevmo prescribing information
- Selpercatinib (AHFS Monograph)
Related treatment guides
- Non Small Cell Lung Cancer
- Solid Tumors
- Thyroid Cancer
